Related Experiment Video
Updated: Jan 22, 2026

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria
Published on: May 16, 2025
Programmed Death 1 Inhibitor-Induced Hypothyroidism on the Palliative Care Unit: Case Report
1Department of Medicine, University of British Columbia, Kelowna, British Columbia, Canada.
Abstract:
Novel immune-based cancer therapies such as programmed death 1 (PD-1) inhibitors continue to emerge for both curative and palliative intent. Post-market data of PD-1 inhibitors indicate that there are a wide range of side effects associated with these drugs, including ones that have relevance to symptom control and represent a diagnostic challenge at the end of life. We present a case of pembrolizumab-induced hypothyroidism causing extreme fatigue and persistent hypoglycemia.
Insights
Novel cancer therapies like PD-1 inhibitors can cause side effects. This case highlights pembrolizumab-induced hypothyroidism leading to fatigue and hypoglycemia, posing end-of-life diagnostic challenges.
Area of Science:
- Oncology
- Immunotherapy
- Endocrinology
Background:
- Emergence of novel immune-based cancer therapies, including programmed death 1 (PD-1) inhibitors, for curative and palliative care.
- PD-1 inhibitors represent a significant advancement in cancer treatment.
- Growing body of post-market data on PD-1 inhibitors is revealing a spectrum of associated side effects.
Observation:
- Post-market surveillance of PD-1 inhibitors has identified a broad range of adverse events.
- Some side effects are particularly relevant to symptom management and pose diagnostic difficulties in end-of-life care.
- A specific case involving a patient treated with pembrolizumab is presented.
Findings:
- The patient developed hypothyroidism as a direct result of pembrolizumab treatment.
- This drug-induced hypothyroidism manifested as extreme fatigue.
- Persistent hypoglycemia was also observed as a consequence of the treatment.
Implications:
- Pembrolizumab-induced hypothyroidism can present significant challenges in symptom control for cancer patients.
- Accurate diagnosis of treatment-related side effects is crucial, especially in palliative and end-of-life settings.
- This case underscores the importance of monitoring endocrine function during PD-1 inhibitor therapy.
Related Concept Videos
Measurement: Standard Units
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Measurement: Derived Units
Data Reporting and Recording
Motor Units
Motor Units
Motor units come in different sizes, with smaller units...

